Amorepacific has made a strategic investment in Junevity through its corporate venture arm, Amorepacific Ventures, and paired it with a research collaboration aimed at next-generation products for skin ageing.

The deal, announced September 29, joins Junevity's RESET Platform with Amorepacific's expertise in skin biology, cosmetic formulation and commercialisation. Amorepacific has also signed a separate licensing agreement covering cosmetic applications, under which the Korean beauty group will lead development and commercialisation of any products that emerge from the research.

Junevity, for its part, retains its therapeutic pipeline. The biotechnology company will continue developing therapeutic applications of its platform independently of the cosmetics partnership.

How the RESET Platform works

Junevity's technology rests on three inputs: human disease omics, genetic linkages, and machine learning with AI. Together, these tools identify transcription factor targets — the regulatory proteins that control suites of downstream genes.

The partnership's scientific goal is ambitious. The two companies want to discover and validate pathways capable of resetting ageing skin gene networks toward a healthier state. In practice, that means intervening not at the level of single markers of photoageing or senescence, but at the control nodes that govern how skin cells express entire gene programmes.

Whether that ambition translates into measurable clinical endpoints — improved barrier function, epidermal turnover, dermal matrix remodelling — remains to be demonstrated. The companies have not disclosed timelines, financial terms of the investment, or the size of the equity stake.

Strategic logic

For Amorepacific, the deal extends a longevity-focused skin science strategy. It brings biotechnology, AI and gene-network research directly into the group's cosmetics R&D pipeline, positioning the company to identify mechanisms of skin ageing and rejuvenation that conventional cosmetic active discovery — largely built on antioxidant, peptide and retinoid chemistry — does not reach.

The structure of the agreement follows a pattern increasingly common among major beauty players: invest early through a venture vehicle, license cosmetic rights narrowly, and leave therapeutic development to the biotech partner. L'Oréal, Shiseido and others have struck comparable arrangements in recent years as the boundary between cosmeceutical and biotech discovery continues to blur.

For dermatology practitioners, the significance is prospective. If the RESET Platform validates gene-network targets in ageing skin, downstream cosmetic products would represent a mechanistically novel category — actives selected for their effect on transcriptional regulators rather than on isolated molecular pathways.

No products, formulations or launch dates have been announced. The next milestone to watch is validation data from the joint research programme, which will determine whether transcription factor resetting can move from computational target identification to demonstrable effects in human skin.